相关实验视频
Updated: May 15, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
通过使用大量组合遗传学 (CombiGEM) 识别的协同miRNA组合来缓解多克索鲁比心脏毒性
Yasutomi Higashikuni1, Colin Platt2, Margaret H Hastings3
1Division of Cardiovascular and Genetic Research, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan; Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan; Synthetic Biology Group, MIT Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
研究人员发现,miR-222和miR-455的组合可以保护心脏细胞免受化疗损伤. 这一发现为新的心脏保护疗法提供了潜在的可能性,以防止多克索鲁比诱导的心脏毒性.
科学领域:
- 心血管生物学 心血管生物学
- 分子遗传学 分子遗传学
- 药物发现 药物发现 药物发现
背景情况:
- 化疗,如多克索鲁比,导致心肌细胞损失,导致心力衰竭.
- 需要有效的心脏保护策略来预防心脏损伤,而不会降低化疗的疗效.
研究的目的:
- 为了确定增强心肌细胞存活的微RNA (miRNA) 组合.
- 发现新的治疗点,以预防化疗引起的心脏毒性.
主要方法:
- 在心肌细胞细胞系中利用大规模并行组合基因查 (CombiGEM).
- 在初级心肌细胞和体内模型 (小鼠,斑马鱼) 中验证的顶部miRNA组合的多克索鲁比心脏毒性.
- 采用RNA测序来阐明潜在的分子机制.
主要成果:
- 确定了多个miRNA组合,在体外给予对多克索鲁比的保护.
- 结合miR-222和miR-455在体外表现出协同的心脏保护,并在体内减轻心脏毒性.
- RNA测序揭示了线粒体平衡,氧化应激和肌肉收缩通路的协同调节.
结论:
- miR-222和miR-455代表了心脏保护的有前途的治疗组合.
- 这项研究突出了CombiGEM在发现组合miRNA疗法的潜力.
- 进一步了解miRNA在心脏保护和对心脏毒剂的反应中的作用.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:09A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
相关概念视频
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Heart Failure Drugs: Inotropic Agents